dateOfBirth,filename,therapy,drugClass,tissue,variant,evidenceType,association,status,url,pubMedId,fdaApproved,isOnLabel,Age
1984-08-29,result_e8a622a1-ac51-4bb7-b0a4-58bdc37ac78f-HRDv1_4.json,,,,,,,,,,,,38
1984-08-29,result_e8a622a1-ac51-4bb7-b0a4-58bdc37ac78f-HRDv1_4.json,,,,,,,,,,,,38
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Regorafenib,Multi-TKI,Colorectal Cancer,p.g12d,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/23177514,23177514,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Cetuximab or Panitumumab,Anti-EGFR MAb,Colorectal Cancer,p.g12d,therapeutic,resistance,Consensus,,NCCN,True,True,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Erlotinib + Capecitabine,Combination (EGFR Inhibitor + Pyrimidine Analog),Colorectal Cancer,p.g12d,therapeutic,adverse outcome,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/28045335,28045335,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Adoptive T-Cell Transfer,Adoptive Cell Therapy,Colorectal Cancer,p.g12d,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/27959684,27959684,False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1784fs,therapeutic,response,Consensus,,NCCN,True,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.q670fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,0
1984-00-00,result_181c18f3-19f1-4229-a94a-4223c0af9125-xTv1_4_ed_SK.json,Capivasertib,Pan-AKT Inhibitor,Solid Tumors,p.e17k,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/28489509,28489509,False,False,0
1984-08-29,result_dd60068c-d70f-460d-bfc5-59fbb7e88919-RNAv1_4.json,,,,,,,,,,,,38
1984-08-29,result_dd60068c-d70f-460d-bfc5-59fbb7e88919-RNAv1_4.json,,,,,,,,,,,,38
1984-08-29,result_1fe38f5f-45f9-4ef8-b4bb-0fb49b053446-PD-L122c3v1_4.json,,,,,,,,,,,,38
1984-08-29,result_1fe38f5f-45f9-4ef8-b4bb-0fb49b053446-PD-L122c3v1_4.json,,,,,,,,,,,,38
1984-08-29,result_0b40a97b-5fc8-422e-8f1a-cbca8b7b02e1-MMRv1_4.json,,,,,,,,,,,,38
1984-08-29,result_0b40a97b-5fc8-422e-8f1a-cbca8b7b02e1-MMRv1_4.json,,,,,,,,,,,,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib,PARP Inhibitor,Endometrioid Endometrial Adenocarcinoma,p.r130g,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/21468130,21468130,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Everolimus,mTOR Inhibitor,Prostate Cancer,p.r130g,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/23582881,23582881,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Niraparib or Rucaparib,PARP Inhibitor,Ovarian Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Olaparib or Talazoparib,PARP Inhibitor,Her2 Negative Breast Cancer,p.n1034fs,therapeutic,response,Consensus,,NCCN,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Cancer,p.n1034fs,therapeutic,response,Case study,http://www.ncbi.nlm.nih.gov/pubmed/25964244,25964244,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,RXC004,Porcupine Inhibitor,Gastric Cancer,p.v50fs,therapeutic,response,Preclinical,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14094,ASCO 2017 (abstr e14094),False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r273c,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Adavosertib,WEE1 Inhibitor,Solid Tumors,p.r110p,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/27601554,27601554,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,CI-1040 or Hypothemycin or PD-0325901 or Selumetinib or PD98059,MEK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,SP-600125 or BI78D3 or AEG3482,JNK Inhibitor,Cancer,p.k567e,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/25284480,25284480,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r579*,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r579*,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Vorinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,LY3295668,AURK Inhibitor,Cancer,p.r73fs,therapeutic,response,Preclinical,https://www.ncbi.nlm.nih.gov/pubmed/30373917,30373917,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Trichostatin or Entinostat,HDAC Inhibitor,Retinoblastoma,p.r73fs,therapeutic,response,Preclinical,http://www.ncbi.nlm.nih.gov/pubmed/18483379,18483379,False,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Copanlisib,PI3K Inhibitor,Endometrial Cancer (w/ PTEN LOF),p.h1047r,therapeutic,response,Clinical research,http://www.ncbi.nlm.nih.gov/pubmed/27672108,27672108,True,False,38
1984-08-29,result_92395d0b-2963-49af-bae1-197c82126aff-xFv1_4.json,Capivasertib,Pan-AKT Inhibitor,Gynecologic Cancers,p.h1047r,therapeutic,response,Clinical research,https://www.ncbi.nlm.nih.gov/pubmed/29066505,29066505,False,False,38
